Clinical Trial: Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Observational
Official Title: Utility of Aberrant Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers
Brief Summary: This study is to identify potential markers from esophageal biopsies and brush cytology for feasibility of use in stool specimens for detection of Barretts Esophagus.
Detailed Summary:
Sponsor: Mayo Clinic
Current Primary Outcome: to determine if assay of aberrantly methylated gene markers can discriminate Barrett's Esophagus tissue (and presence of dysplasia) from esophageal squamous and gastric cardia tissue. [ Time Frame: 1 day ]
Original Primary Outcome: to determine if assay of aberrantly methylated gene markers can discriminate Barrett's Esophagus tissue from esophageal squamous and gastric cardia tissue. [ Time Frame: 1 day ]
Current Secondary Outcome: Assess the accuracy of candidate markers in stool for detection of Barrett's Esophagus [ Time Frame: One day ]
Original Secondary Outcome: Same as current
Information By: Mayo Clinic
Dates:
Date Received: February 3, 2014
Date Started: May 2012
Date Completion: May 2017
Last Updated: September 15, 2016
Last Verified: September 2016